Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma
Addition of oxaliplatin or nab-paclitaxel to nal-IRI/FL was significantly associated with a better OS than regimen shifting after progression on nal-IRI/FL in patients with metastatic PDAC.
Authors
- Yan‐Shen Shan (ORCID: https://orcid.org/0000-0002-2457-5189)
- Shih‐Hung Yang (ORCID: https://orcid.org/0000-0002-8572-4977)
- Sung‐Hsin Kuo (ORCID: https://orcid.org/0000-0003-0054-887X)
- Sz-Chi Chiu
- Hsiang‐Fong Kao (ORCID: https://orcid.org/0000-0001-9186-0134)
- Kun‐Huei Yeh (ORCID: https://orcid.org/0000-0002-7306-174X)
- Chien‐Jui Huang (ORCID: https://orcid.org/0000-0002-5503-9266)
- Li‐Chun Lu (ORCID: https://orcid.org/0000-0001-8975-9491)
Institutions
- National Taiwan University Hospital (TW)
- National Cheng Kung University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Journal of the Formosan Medical Association
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1016/j.jfma.2025.02.035
- Citations
- 3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14